Log in to save to my catalogue

Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with...

Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A826307340

Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with Type 1 or Type 2 Diabetes

About this item

Full title

Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with Type 1 or Type 2 Diabetes

Publisher

Springer

Journal title

Diabetes Therapy, 2025, Vol.16 (2), p.241

Language

English

Formats

Publication information

Publisher

Springer

More information

Scope and Contents

Contents

It is widely accepted that the higher the number of medications prescribed and taken by an individual, the higher the risk of poor health outcomes. We have investigated whether polypharmacy and comorbidities conveyed more risk of adverse health outcomes following COVID-19 infection (as a paradigm of serious viral infections in general) in people wi...

Alternative Titles

Full title

Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with Type 1 or Type 2 Diabetes

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A826307340

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A826307340

Other Identifiers

ISSN

1869-6953

DOI

10.1007/s13300-024-01681-9

How to access this item